- Home
- SOFI vs MRNA Comparison
SOFI vs MRNA Comparison
Compare SOFI & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOFI
- MRNA
- Stock Information
- Founded
- SOFI 2011
- MRNA 2010
- Country
- SOFI United States
- MRNA United States
- Employees
- SOFI N/A
- MRNA N/A
- Industry
- SOFI Diversified Financial Services
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOFI Finance
- MRNA Health Care
- Exchange
- SOFI Nasdaq
- MRNA Nasdaq
- Market Cap
- SOFI 16.1B
- MRNA 16.0B
- IPO Year
- SOFI N/A
- MRNA 2018
- Fundamental
- Price
- SOFI $17.90
- MRNA $35.89
- Analyst Decision
- SOFI Hold
- MRNA Hold
- Analyst Count
- SOFI 16
- MRNA 20
- Target Price
- SOFI $11.36
- MRNA $76.35
- AVG Volume (30 Days)
- SOFI 36.9M
- MRNA 10.7M
- Earning Date
- SOFI 01-27-2025
- MRNA 02-20-2025
- Dividend Yield
- SOFI N/A
- MRNA N/A
- EPS Growth
- SOFI N/A
- MRNA N/A
- EPS
- SOFI 0.12
- MRNA N/A
- Revenue
- SOFI $2,519,211,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- SOFI N/A
- MRNA N/A
- Revenue Next Year
- SOFI $18.09
- MRNA N/A
- P/E Ratio
- SOFI $151.08
- MRNA N/A
- Revenue Growth
- SOFI 32.15
- MRNA N/A
- 52 Week Low
- SOFI $6.01
- MRNA $31.94
- 52 Week High
- SOFI $18.10
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- SOFI 67.66
- MRNA 40.41
- Support Level
- SOFI $13.60
- MRNA $33.34
- Resistance Level
- SOFI $15.62
- MRNA $35.68
- Average True Range (ATR)
- SOFI 0.70
- MRNA 2.53
- MACD
- SOFI 0.21
- MRNA -0.60
- Stochastic Oscillator
- SOFI 95.56
- MRNA 23.26
About SOFI SoFi Technologies Inc.
SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.